Contracts › 75F40123C00210
75F40123C00210: Examine the Impact of a Benzodiazepine (BZD) Care Plan (BCP) and Electronic Health Record (EHR) Bzd Prescribing S, in Parallel With Provider Education, on Bzd Prescribing.
Awarded to Kaiser Foundation Hospitals by Food and Drug Administration (FDA).
$1.2Mobligated
$1.2Mpotential value
29 September 2026current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75F40123C00210 |
|---|---|
| Awardee | Kaiser Foundation Hospitals |
| Awarding agency | Food and Drug Administration (FDA) |
| Awarding office | FDA OFFICE OF ACQ GRANT SVCS |
| NAICS | 541714 Research and Development in Biotechnology (Except Nanobiotechnology) |
| PSC | AN11 Health R&D Services; Health Care Services; Basic Research |
| Place of performance | MD |
| Offers received | 1 |
| Period of performance | 25 September 2023 to 29 September 2026 |
| Potential end | 29 September 2026 |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 04 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541714 contracts · All expiring contracts · USASpending record